22:50 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: B cell lymphoma Cell and mouse studies suggest promoting PMAIP1 expression or inhibiting MCL1 could enhance the efficacy of BCL-2 inhibitors to treat diffuse large B cell lymphoma (DLBCL). In a DLBCL cell line,...
07:00 , Aug 27, 2009 |  BC Innovations  |  Targets & Mechanisms

Melanoma: eaten up inside

Autophagy's dual pro- and antiapoptotic roles make it hard to determine whether inducing the process could be a viable strategy to treat cancer. In melanoma, a team led by Spanish researchers thinks the answer is...
07:00 , Aug 13, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Interferon induced with helicase C domain 1 (IFIH1; MDA5); phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1; NOXA) Studies in cell culture and in mice suggest that double-stranded...
08:00 , Jan 29, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Hematological malignancies Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1; NOXA); ER-associated protein degradation (ERAD) Studies in cell culture suggest that Eeyarestatin I (EerI) may...